Abstract: Ratios of measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a subject to measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a healthy subject are calculated, and the glucose ratio, the citrate ratio, and the cis-aconitate ratio are used to evaluate and/or assess fatigue. Similarly, an isocitrate ratio, a succinate ratio, a malate ratio, and a lactate ratio are calculated, and these ratios are used together with the three ratios to evaluate and/or assess fatigue. This makes it possible to objectively and easily diagnose and evaluate fatigue.

Abstract: A thermally conductive sheet includes a mesh sheet and a thermally conductive composition containing a resin composition and a thermally conductive filler and coating both sides of the mesh sheet so as to form a thermally conductive layer. The thermally conductive sheet is prevented from trapping air bubbles so as to exhibit high thermal conductivity, and is so strong that does not easily tear. The mesh sheet has mesh holes defined by thread intersecting with each other. The intersection of the threads is provided with an bubble inclusion inhibition part for preventing air bubbles from being trapped in the interface between the thermally conductive composition and the mesh sheet. The bubble inclusion inhibition part may be a fused portion, a pressure-bonded portion or the like.

Abstract: An inorganic fine particle layer containing inorganic fine particles and a binder component is formed on a surface of a substrate by chemical bonding. The inorganic fine particles are coated with silane monomer each having an unsaturated bond. The content of the binder component is in the range of 0.1% by mass to 40% by mass to the content of the inorganic fine particles.

Abstract: A label with which labeling is easy when labeling a molecule, i.e., a label that has a high reaction rate upon labeling and that produces a high reaction yield, as well as a precursor for the production of the label are provided. This is achieved by a hexatriene-?-carbonyl compound represented by Formula (I), a hexatriene-?-carbonyl compound represented by Formula (II), a hexatriene-?-carbonyl compound represented by Formula (III) and a hexatriene-?-carbonyl compound represented by Formula (IV).

Abstract: The present invention provides a clinically usable radiolabeled compound that is precisely directable in vivo to a target tissue. The compound of the present invention has a first polypeptide or an analogue thereof, and a second polypeptide bonded to an N-terminus of the first polypeptide or the analogue thereof. In the compound, the first polypeptide is a polypeptide that specifically binds with a protein expressed in a target tissue, the second polypeptide has an amino acid region that has a high affinity for a radioactive metal nuclide, and the radioactive metal nuclide that has a high affinity for the amino acid region is held in the amino acid region.

Abstract: A labeling compound of the present invention includes a structure represented by formula (1) wherein X1 is 11CH3, CH218F, CF218F, 18F, 76Br or 124I, X2 is CN or NO2, and R is any one of groups represented by or a structure represented by formula (2) wherein X3 is CH3, CH2F, CF3, F, Br or I, and R is defined equally as in the formula (1). This allows realizing a labeling compound for PET, capable of quantifying aromatase with high accuracy.

Abstract: A pancreatic endocrine cell indicating agent of the present invention includes a modified polypeptide in which a metal chelator binds only to an amino acid that is located at a site other than a somatostatin receptor-binding active site in a polypeptide selected from the group consisting of somatostatin and somatostatin analogs; and a radioactive metal nuclide held by the metal chelator. According to the present invention, it is therefore possible to provide a novel pancreatic endocrine cell indicating agent.

Abstract: Disclosed are: labeled NSAIDs compounds which can be produced within a short time, can be used suitably for a PET method, and enable the imaging of cyclooxygenase-2; and a process for producing the labeled NSAIDs compounds. Specifically disclosed are isotope-labeled 2-arylpropionic acid compounds, each of which is a compound represented by general formula (1) (wherein Ar represents an aryl group which may have a substituent; R1 represents anyone selected from 11CH3, CH218F and CF218F; and R2 represents a hydrogen atom, or an alkyl group which may have a branch, wherein a compound wherein Ar is a benzene ring, R1 is 11CH3, and R2 is a hydrogen atom is excluded), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

Abstract: [OBJECT] The present invention provides an 18F-labeled azide compound usable in the Huisgen reaction which enables 18F-labeling although only a small quantity of alkyne compound is available as a counterpart substrate, more specifically the 18F-labeled azide compound enabling the PET to be applied to peptides or oligonucleotides and enabling the 18F-labeling of any sites of oligonucleotide other than the 5? end or 3? end thereof, a reagent for 18F-labeling, and a method for 18F-labeling of an alkyne compound using the same. [SOLVING MEANS] An 18F-labeled azide compound according to the present invention is expressed by the following structural formula 1.

Abstract: A human fatigue assessment device capable of performing highly accurate fatigue assessment is provided.

Abstract: The present invention provides a method of determining whether or not a subject is affected with chronic fatigue syndrome (CFS) comprising: measuring, in a biological sample from the subject, an expression level of a transcript of at least one gene respectively from at least two gene groups selected from six specific gene groups; calculating a value representing a deviation of the measured expression level based on an expression level of a transcript of the corresponding gene in a population of healthy subjects; obtaining an average of the value(s) representing a deviation; and determining whether or not the subject is affected with CFS by using the average.

Abstract: The invention provides a method for introducing 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (DOTA) into a compound such as a peptide. The method comprises a first step for preparing a mixed liquid of DOTA having no protecting group and dimethylsulfoxide, and a second step for contacting the mixed liquid with the compound carried on a solid-phase carrier.

Abstract: Novel calcium-independent phospholipases A2; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases A2 having an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus with kainic acid or an electrical stimulus; a method of regulating expression by using the gene; and an organism having the gene transferred thereinto.

Abstract: An object of the present invention is to provide apparatuses for examining/diagnosing clinical disease of cancer, systemic lupus erythematosus (SLE), or antiphospholipid antibody syndrome. Blood, blood-derived component, urine, sweat, nail, skin, or hair is irradiated with light having a wavelength of 400 to 2,500 nm or a part of the range, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic absorbance data, and afterward a previously prepared analysis model is used to analyze the absorbance over the whole wavelengths or at a specific wavelength for the measurement to allow the achievement of the object.

Abstract: A label with which labeling is easy when labeling a molecule, i.e., a label that has a high reaction rate upon labeling and that produces a high reaction yield, as well as a precursor for the production of the label are provided. This is achieved by a hexatriene-?-carbonyl compound represented by Formula (I), a hexatriene-?-carbonyl compound represented by Formula (II), a hexatriene-?-carbonyl compound represented by Formula (III) and a hexatriene-?-carbonyl compound represented by Formula (IV).

Abstract: The present invention is a method and an apparatus for examination/diagnosis of lifestyle related disease, wherein the test sample from a human or other animal subject is irradiated with light having a wavelength region of a region of 400 nm-2,500 nm or a part of the region, of which the reflection light, the transmission light, or the transmission reflection light is then detected to give spectroscopic data of absorbance, and afterward a previously prepared analysis model is used to execute an analysis of the absorbance at the whole or specific wavelength used for the measurement.

Abstract: [Object] To provide a dustproof, antifouling, and highly durable composite material. [Solving Means] An inorganic fine particle layer containing inorganic fine particles and a binder component is formed on a surface of a substrate by chemical bonding. The inorganic fine particles are coated with silane monomer each having an unsaturated bond. The content of the binder component is in the range of 0.1% by mass to 40% by mass to the content of the inorganic fine particles.

Abstract: Novel calcium-independent phospholipases A2; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases A2 having an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus with kainic acid or an electrical stimulus; a method of regulating expression by using the gene; and an organism having the gene transferred thereinto.

Abstract: Novel calcium-independent phospholipases A2; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases A2 having an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus with kainic acid or an electrical stimulus; a method of regulating expression by using the gene; and an organism having the gene transferred thereinto.

Abstract: Methods and reagents for rhodium-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.